glp·helper
glphelper.com/ozempic/delaware/wilmington
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Wilmington, DE

Verified Ozempic providers in Wilmington, DE. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
38
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Delaware
38 of 38 shown

Find an Ozempic provider in Delaware.

Every entry is checked against the NPI registry and the Delaware medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Delaware city · /ozempic/delaware/{city}
§ 03Getting Ozempic in Wilmington
38 providers · Wilmington, DE

How to get Ozempic in Wilmington.

38 GLP-1 prescribers and 7 local resource types are on record for Wilmington, plus 1 nearby town in the directory.

Prescribers in Wilmington
38 prescribers
38 GLP-1 prescribers in Wilmington, most listed as Family Medicine (14), Internal Medicine, Endocrinology, Diabetes & Metabolism (12) and Internal Medicine (10). Any Delaware-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Dover (37 providers).
Around the prescription in Wilmington
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 5 places to move are on record near Wilmington.
Medicaid (weight loss)
Covered
As of April 2026, Delaware Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Delaware’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Delaware

Diagnosed diabetes reaches 11.1% of adults in Delaware.

of Delaware adults have obesity
36.6%
diagnosed diabetes
11.1%

Age-adjusted estimates for Delaware, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossOzempic babies explained
§ 05Support around Ozempic in Wilmington
6 dietitians

The prescription is one part. Here is the rest, in Wilmington.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Wilmington, DE, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Melinda Allen, MA, RD, LDN
RD
Registered dietitian
1601 Kirkwood Hwy
Call 302-994-2511NPI 1083150106
Alicia Aronovich, RD
RD
Registered dietitian
1600 Rockland Rd
Call 302-651-4000NPI 1932638780
Alyssa Atanacio, RD, LDN
RD
Registered dietitian
3506 Kennett Pike
Call 302-661-3043NPI 1831569854
Elizaveta Azeeva, RDN
RD
Registered dietitian
2810 N Church St
Call 773-906-4773NPI 1033966635
Maria Bair, RD
RD
Registered dietitian
1125 N Bancroft Pkwy
Call 302-377-8957NPI 1841315264
Christine Bannon, RD, LDN
RD
Registered dietitian
1601 Kirkwood Hwy
Call 610-717-6554NPI 1265133136

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Elizabeth Abel
NUTRITIONIST
Nutritionist
811 Augusta Rd
Call 302-893-3801NPI 1356702179
Payton Baker, MS, RD
NUTRITIONIST
Nutritionist
2810 N Church St
Call 402-841-0853NPI 1922889351
Anna Bakhshi, CNS
NUTRITIONIST
Nutritionist
2810 N Church St
Call 773-906-4773NPI 1265208953
Junior Jean-Paul, MS,CNS, CNGS
NUTRITIONIST
Nutritionist · Education
115 Christina Landing Dr Apt 807
Call 646-469-4477NPI 1346989340
Rachel Naumann, MS, CNS, CDN
NUTRITIONIST
Nutritionist
2810 N Church St Pmb 55508
Call 773-906-4773NPI 1477367464
Kelli Obrien, CNS Candidate
NUTRITIONIST
Nutritionist
5 Elsmere Blvd
Call 540-809-5784NPI 1063274124
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Delaware

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Delaware

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]